Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, ...
A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and ...
Christopher J. Sayed, MD, anticipates exciting advancements in hidradenitis suppurativa (HS) at the 2025 American Academy of Dermatology Annual Meeting. With numerous ongoing phase 2 and phase 3 ...
The American Academy of Dermatology (AAD) recently issued a focused update to its guidelines on the management of atopic dermatitis (AD) in adults, strongly recommending four recently approved ...
SCOTCH PLAINS, N.J.--(BUSINESS WIRE)--Navigator Medicines, Inc., a clinical-stage biotech company leading the advancement of biologics for targeted immune regulation and restoration, today announced ...
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of ...
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) By Eli Lilly and Company, Incyte, American Academy of Dermatology (AAD) Annual Meeting Late-breaking results presented at AAD show 80% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback